

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

## 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

## 5. Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1.	Identifying Inform	ation							
1. Given Name (Fi Brian	rst Name)	2. Surname (Last Nar Feagan	ne)	3. Date 05-November-2018					
4. Are you the cor	responding author?	✓ Yes No							
	5. Manuscript Title 2017-2018 ECCO Disclosures								
6. Manuscript Identifying Number (if you know it) ECCO-									
Section 2. The Work Under Consideration for Publication									
Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest? Yes No  If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.									
Name of Institut	,,	Grant? Personal Fees?	Non-Financial Support?	Other?	Comments				
Section 3.	Relevant financial a	activities outside	the submitted	work.					
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes No  If yes, please fill out the appropriate information below.									
Name of Entity		Grant? Personal Fees?	Non-Financial Support?	Other?	Comments				
AbbVie		<b>V</b>			Research Support; Consultant; Speaker Bureau; Advisory Board Member				
Actogenix					Consultant				



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Akros		✓			Consultant
Albireo Pharma		✓			Consultant
Allergan		$\checkmark$			Consultant; Advisory Board Member
Amgen	<b>✓</b>	<b>✓</b>			Research Support; Consultant; Advisory Board Member
Astra Zeneca	<b>✓</b>	<b>✓</b>			Research Support; Consultant: Advisory Board Member
Avaxia Biologics Inc		$\checkmark$			Consultant; Advisory Board Member
Avir Pharma		✓			Consultant
Atlantic Pharma		<b>✓</b>			Research Support; Consultant; Advisory Board Member
Baxter Healthcare Corporation		<b>✓</b>			Consultant
Biogen Idec		✓			Consultant
Boehringer-Ingelheim		✓			Consultant; Advisory Board Member
Bristol-Myers Squibb (BMS)	<b>✓</b>	<b>✓</b>			Research Support; Consultant; Advisory Board Member
Calypso Biotech		✓			Consultant
Celgene		✓			Consultant; Advisory Board Member
Elan/Biogen		$\checkmark$			Consultant; Advisory Board Member
EnGene		$\checkmark$			Consultant
Ferring		<b>✓</b>			Consultant; Advisory Board Member
Genentech/Roche		$\checkmark$			Consultant; Advisory Board Member
GiCare Pharma		<b>✓</b>			Consultant
Gilead		<b>✓</b>			Consultant
Given Imaging		<b>✓</b>			Consultant
GSK		<b>✓</b>			Consultant
Ironwood		<b>✓</b>			Consultant
Janssen Biotech/Centocor	<b>✓</b>	<b>✓</b>			Research Support; Consultant
JnJ/Janssen	<b>✓</b>	<b>✓</b>			Research Support; Consultant: Speaker Bureau; Advisory Board Member
Kyowa Kakko Kirin Co Ltd		$\checkmark$			Consultant
Lilly		<b>✓</b>			Consultant



Lycera Biotech		<b>✓</b>		Consultant
Merck		<b>✓</b>		Consultant; Advisory Board Member
Mesoblast Pharma		<b>✓</b>		Consultant
Millennium		<b>✓</b>		Consultant; Advisory Board Member
Nestles		<b>✓</b>		Consultant; Advisory Board Member
Novo Nordisk		<b>✓</b>		Consultant; Advisory Board Member
Novartis		<b>✓</b>		Consultant; Advisory Board Member
Pfizer	<b>✓</b>	<b>✓</b>		Research Support; Consultant; Advisory Board Member
Prometheus Therapeutics & Diagnostics		<b>✓</b>		Consultant; Advisory Board Member
Protagonist		<b>✓</b>		Consultant; Advisory Board Member
Receptos	<b>✓</b>	<b>✓</b>		Research Support; Consultant; Advisory Board Member
Salix		<b>✓</b>		Consultant; Advisory Board Member
Sanofi	<b>✓</b>			Research Support
Shire		<b>✓</b>		Consultant
Sigmoid Pharma		<b>√</b>		Consultant; Advisory Board Member
Synergy Pharma		<b>✓</b>		Consultant
Takeda	<b>✓</b>	<b>√</b>		Research Support; Consultant; Speaker Bureau; Advisory Board Member
Teva Pharma		<b>√</b>		Consultant; Advisory Board Member
TiGenix		<b>✓</b>		Consultant; Advisory Board Member
Tillotts		<b>✓</b>		Research Support; Consultant; Advisory Board Member
UCB		<b>✓</b>		Research Support; Consultant; Advisory Board Member; Speaker Bureau
Vertex		<b>✓</b>		Consultant
VHsquared		<b>√</b>		Consultant
Wyeth		<b>✓</b>		Consultant
Zealand		<b>✓</b>		Consultant
Zyngenia		<b>✓</b>		Consultant
Galapagos		<b>✓</b>		Consultant: Scientific Advisory Board
Inception IBD Inc		<b>✓</b>		Consultant



Lexicon		<b>✓</b>			Consultant		
Vivelix Pharma		<b>✓</b>			Consultant		
Japan Tobacco Company		$\checkmark$			Consultant		
Ablynx		$\checkmark$			Consultant		
Progenity		$\checkmark$			Consultant		
NextBiotix		<b>✓</b>			Consultant		
Gossamer Pharma		<b>✓</b>			Consultant		
Qu Biologics		<b>✓</b>			Consultant		
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo							
Section 5. Polotionships not a							
Relationships not o	overed a	above					
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?							
✓ Yes, the following relationships/conditions/circumstances are present (explain below):							
✓ Yes, the following relationships/cond	iitiOiis/Cii	Lumstances	are present (ex	plain bel	ow):		
Yes, the following relationships/conditions/cir							

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.



#### Section 6.

#### **Disclosure Statement**

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Feagan reports grants and personal fees from AbbVie, personal fees from Actogenix, personal fees from Akros, personal fees from Albireo Pharma, personal fees from Allergan, grants and personal fees from Amgen, grants and personal fees from Astra Zeneca, personal fees from Avaxia Biologics Inc, personal fees from Avir Pharma, personal fees from Atlantic Pharma, personal fees from Baxter Healthcare Corporation, personal fees from Biogen Idec, personal fees from Boehringer-Ingelheim, grants and personal fees from Bristol-Myers Squibb (BMS), personal fees from Calypso Biotech, personal fees from Celgene, personal fees from Elan/Biogen, personal fees from EnGene, personal fees from Ferring, personal fees from Genentech/Roche, personal fees from GiCare Pharma, personal fees from Gilead, personal fees from Given Imaging, personal fees from GSK, personal fees from Ironwood, grants and personal fees from Janssen Biotech/Centocor, grants and personal fees from JnJ/Janssen, personal fees from Kyowa Kakko Kirin Co Ltd, personal fees from Lilly, personal fees from Lycera Biotech, personal fees from Merck, personal fees from Mesoblast Pharma, personal fees from Millennium, personal fees from Nestles, personal fees from Novo Nordisk, personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Prometheus Therapeutics & Diagnostics, personal fees from Protagonist, grants and personal fees from Receptos, personal fees from Salix, grants from Sanofi, personal fees from Shire, personal fees from Sigmoid Pharma, personal fees from Synergy Pharma, grants and personal fees from Takeda, personal fees from Teva Pharma, personal fees from TiGenix, personal fees from Tillotts, personal fees from UCB, personal fees from Vertex, personal fees from VHsquared, personal fees from Wyeth, personal fees from Zealand, personal fees from Zyngenia, personal fees from Galapagos, personal fees from Inception IBD Inc, personal fees from Lexicon, personal fees from Vivelix Pharma, personal fees from Japan Tobacco Company, personal fees from Ablynx, personal fees from Progenity, personal fees from NextBiotix, personal fees from Gossamer Pharma, personal fees from Qu Biologics, outside the submitted work; and Senior Scientific Officer -Robarts Clinical Trials Inc, Western University, London, Ontario, Canada.

#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.